We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future

Our 10-year strategy













- UK in top quartile of health systems for access and uptake
- Increased medicines uptake with measurable impact on outcomes
- Medicines spend grows in line with patient demand
- New payment models recognise long-term value of innovative therapies





- UK reaches 2.4% GDP target for R&D and increases share of manufacturing for innovative medicines
- Recognition that R&D and manufacturing is vital to the economy
- Clinical research performance continues to improve
- UK retains global R&D thought leadership

- Industry viewed as a true partner to the NHS
- Cross-sector collaborations benefitting patients, the NHS and the economy
- Increase in value of UK life sciences

Ensuand we me now and vaccine future and vaccine future

Build better partnerships between industry and NHS and across Life Sciences sector







NHS and across
Life Sciences
sector





- Fully integrated NHS data sets, well governed and accessible to industry
- UK is more attractive for cutting-edge research collaboration and evidence generation

capability as health access to industry;



Provide international Provide international Iteratership and drive I leadership alpolicy

- Regulatory and trade environments are positively influenced through driving global policy
- ABPI and UK affiliates seen as key to shaping UK view on international issues
- ABPI and our members shape UK policy on international issues

manufacturing ench,








Build a stronger industry reputation in the UK

- Government, NHS, healthcare professionals and patients will advocate for the pharmaceutical industry
- Government confident in championing the sector

international drive

We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future

Our 10-year strategy



Underpinned by members